Literature DB >> 22209337

Non-fatal cardiovascular disease, malignancies, and other co-morbidity in adult haemophilia patients.

Dietje E Fransen van de Putte1, Kathelijn Fischer, Astrid E Pulles, Goris Roosendaal, Douwe H Biesma, Roger E G Schutgens, Eveline P Mauser-Bunschoten.   

Abstract

INTRODUCTION: With increasing life expectancy, more haemophilia patients will be confronted with age-related problems. To ensure optimal care, it is important to know the occurrence of both fatal and non-fatal cardiovascular disease, malignancies and other types of co-morbidity in these patients. Our aim was to retrospectively assess the occurrence of co-morbidity and causes of death in a substantial birth-cohort of haemophilia patients.
METHODS: Data on all types of co-morbidity were collected from medical records of 408 haemophilia patients (204 severe, 204 non-severe) born before 1971, and compared with the Dutch age-matched general male population.
RESULTS: Ten patients had 11 myocardial infarctions, none of which were fatal. The cumulative incidence of non-fatal myocardial infarction was significantly lower in patients with severe haemophilia than in the general population (0.5% versus 4.8%), but was not decreased in patients with non-severe haemophilia (4.4%). Intracranial bleeding occurred significantly more often in haemophilia patients. The occurrence of non-virus related malignancies, and other non-virus related co-morbidities was similar in haemophilia patients and the general population. HIV infection was present in 12% of patients, and hepatitis C infection in 56%. Seventy-eight patients (19%) were deceased. Main causes of death were malignancies, AIDS, hepatitis C, and intracranial bleeding.
CONCLUSIONS: Our results showed a decreased occurrence of myocardial infarction in patients with severe haemophilia, suggesting a protective effect of very low clotting factor levels on thrombotic cardiac events. No differences were found between haemophilia patients and the general population in the occurrence of any other type of non-virus related co-morbidity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22209337     DOI: 10.1016/j.thromres.2011.12.012

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

1.  Pathogen safety of long-term treatments for bleeding disorders: still relevant to current practice.

Authors:  Giovanni Di Minno; Mariana Canaro; James W Ironside; David Navarro; Carlo Federico Perno; Andreas Tiede; Lutz Gürtler
Journal:  Haematologica       Date:  2013-10       Impact factor: 9.941

2.  Risk factors for cardiovascular disease in children and young adults with haemophilia.

Authors:  Jacqueline Limjoco; Courtney D Thornburg
Journal:  Haemophilia       Date:  2018-07-13       Impact factor: 4.287

3.  High prevalence of overweight/obesity in adult persons with hemophilia in Utah and a review of the literature.

Authors:  Ming Y Lim; Guo Wei; Angela P Presson; Paul Bray; George M Rodgers
Journal:  Blood Coagul Fibrinolysis       Date:  2020-12       Impact factor: 1.276

Review 4.  Comorbidities of cardiovascular disease and cancer in hemophilia patients.

Authors:  Jiaan-Der Wang
Journal:  Thromb J       Date:  2016-10-04

Review 5.  Innovative approach for improved rFVIII concentrate.

Authors:  Massimo Morfini
Journal:  Eur J Haematol       Date:  2014-05-22       Impact factor: 2.997

Review 6.  Mortality in congenital hemophilia A - a systematic literature review.

Authors:  Charles R M Hay; Francis Nissen; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

7.  Establishment of a framework for assessing mortality in persons with congenital hemophilia A and its application to an adverse event reporting database.

Authors:  Steven W Pipe; Rebecca Kruse-Jarres; Johnny N Mahlangu; Glenn F Pierce; Flora Peyvandi; Peter Kuebler; Christian De Ford; Fabián Sanabria; Richard H Ko; Tiffany Chang; Charles R M Hay
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

Review 8.  Current Therapeutic Approach to Atrial Fibrillation in Patients with Congenital Hemophilia.

Authors:  Minerva Codruta Badescu; Oana Viola Badulescu; Lacramioara Ionela Butnariu; Mariana Floria; Manuela Ciocoiu; Irina-Iuliana Costache; Diana Popescu; Ioana Bratoiu; Oana Nicoleta Buliga-Finis; Ciprian Rezus
Journal:  J Pers Med       Date:  2022-03-23

9.  A case report of acute inferior myocardial infarction in a patient with severe hemophilia A after recombinant factor VIII infusion.

Authors:  Silva Zupančić-Šalek; Marijo Vodanović; Dražen Pulanić; Boško Skorić; Irina Matytsina; Jolanta Klovaite
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.